We have recruited 3500 patients
Published as lead article in the International Journal of Gynecological Cancer.
Access it here
RESULTS
A total of 3286 patients had a mean age of 60.0 years; 90.6% had high-grade serous carcinoma, and 24.7% presented with FIGO stage IV disease. 50.7% underwent primary cytoreductive surgery, and 49.3% received neoadjuvant chemotherapy. The median follow-up duration was 43.8 months (interquartile range; 22.6-59.3). After propensity score matching (n=1524), overall survival was similar between groups (67.2 vs 65.0 months; HR 1.002, 95% CI 0.85 to 1.18, p=.98). Outcomes differed by ethnicity, residual disease, and post-operative complications.
Post-operative complications (28%) significantly worsened survival (66 vs 46 months; HR 1.5, 95% CI 1.2 to 1.9, p<.001), especially among patients undergoing primary surgery (73 vs 46 months; HR 1.85, 95% CI 1.43 to 2.37, p<.001). The most favorable outcomes were observed among patients with primary surgery, complete resection, and no compli
cations, with median overall survival not reached (HR 1.25, 95% CI 1.12 to 1.40, p<.001)
Why SUROVA?
The primary goal of this initiative is to tackle a critical, unresolved question: whether primary cytoreductive surgery or neoadjuvant chemotherapy followed by interval cytoreductive surgery leads to a higher survival rate (DFS and OS) in patients with high-grade carcinoma of the ovary, fallopian tubes, and peritoneum at FIGO stage IIIB-IVB.
​
How to participate?
You can easily join the study by clicking the yellow button below: it will lead you to a questionnaire to request participation in the study. We are specifically seeking information from patients who have undergone surgery for ovarian cancer stages IIIB-IVB. For additional details and recomendations, please click the link below.
About us
Motivation
This a UNIQUE OPPORTUNITY to answering together some relevant and controversial questions within our Scientific Community on ovarian cancer surgery.
​
We want to take an ACCURATE PICTURE of the real life concerning surgery in ovarian cancer worldwide.
​
Why is your participation important to us?
With your collaboration, this real-life study could become one of the most comprehensive in history, examining the evolution of advanced ovarian cancer.
​
"Many small people, in small places, doing small things can change the world"
Our team
In the SUROVA Study, our medical team comprises some of the most talented and dedicated professionals in ovarian cancer treatment. Our multidisciplinary board includes physicians, statisticians, biologists, and pathologists, working collaboratively to comprehensively address the study and treatment of this disease.
​
Our team is composed of: Luis M. Chiva - Chairman, Pilar Ordás - Cochairman and the trial comitee: Antonio González, José Manuel Aramendía, Luisa Sánchez, Alejandro gallego, Ángel Vizcay, José Ángel Mínguez, Enrique Chacón, Nabil Manzor, Daniel Vázquez, Teresa Castellanos y Nerea Martín.